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Background: Evidence on the role of irisin in insulin resistance is limited and controversial, and pathways between
them remain unknown. We aimed to examine the independent effects of circulating irisin and different adiposity
measurements, as well as their potential interactions, on insulin resistance. We also aimed to explore possible
pathways among circulating irisin, adiposity, glucose and insulin levels and insulin resistance.
Methods: A cross-sectional study of 1,115 community- living obese Chinese adults, with data collection on clinical
characteristics, glucose and lipid metabolic parameters and circulating irisin levels.
Results: Among the 1,115 subjects, 667 (59.8 %) were identified as insulin-resistance, and showed significantly
decreased serum irisin than their controls (log-transformed irisin: 1.19 ± 2.34 v.s. 1.46 ± 2.05 ng/ml, p = 0.042). With
adjustment for potential confounders, elevated circulating irisin was significantly associated with reduced risk of
insulin resistance, with adjusted odds ratio per standard deviation increase of irisin of 0.871 (0.765–0.991, p = 0.036).
As for different adiposity measurements, body fat percentage, but neither BMI nor waist, was significantly
associated with increased risk of insulin resistance (OR: 1.152 (1.041–1.275), p = 0.006). No significant interaction
effect between serum irisin and adiposity on insulin resistance was found. A one pathway model about the
relationship between serum irisin and insulin resistance fits well (χ2 = 44.09, p < 0.001; CFI–0.994; TLI =0.986; and
RMSEA = 0.067), and shows that elevated circulating irisin might improve insulin resistance indirectly through
lowering fasting insulin levels (standardized path coefficient = −0.046, p = 0.032).
Conclusions: Elevated circulating irisin is associated with lower risk of insulin resistance indirectly through lowering
fasting insulin.
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Numerous studies have shown that insulin resistance plays
an important role in the pathogenesis of metabolic syn-
drome [1], type 2 diabetes [2] and cardiovascular disease
[3], but the mechanisms underlying insulin resistance are
not fully understood. Skeletal muscle accounts for the lar-
gest organ of the body in non-obese individuals and has* Correspondence: xmlixuejun@163.com; zhibinli33@hotmail.com
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ducing myokines [4]. Irisin, a newly identified myokine,
drives brown-fat-like conversion of white adipose tissues,
and therefore has been suggested to improve metabolic
and glucose homeostasis [5]. In our two previous publica-
tions, we found that serum irisin levels were negatively as-
sociated with risks of metabolic syndrome [6] and chronic
kidney disease [7], in which the mechanisms of associa-
tions both included insulin resistance. However, existing
evidence on the role of irisin in insulin resistance is
limited and controversial. Moreno-Navarrete JM and co-
workers firstly reported circulating irisin levels were nega-
tively associated with obesity and insulin resistance inle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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positively associated with fasting glucose and homeostasis
model assessment for insulin resistance (HOMA-IR); and
that irisin was independently associated with HOMA-IR in
multiple linear regression analyses after adjustment for con-
founders [9]. Moreover, data on the association between iri-
sin and insulin resistance in obese adults are scarce.
Obesity has been conclusively found to be associated
with increased risks of insulin resistance, type 2 diabetes,
hypertension, cardiovascular disease and cancer [10]. Al-
though body mass index (BMI) has been widely used as
the index of obesity, numerous studies have reported that
BMI and other measures of adiposity, such as waist cir-
cumference, body fat percentage, show different associa-
tions with various health conditions [11–13]. Irisin is
suggested to be not only a myokine but also an adipokine
[14], therefore, effects of different adiposity measure-
ments, as well as their potential interactions with circulat-
ing irisin, on insulin resistance should be explored further.
Bostrom et al. reported that expression of the exercise-
and PGC1-α-induced irisin drives brown fat-like devel-
opment of white fat and protects diet-induced obesity
and diabetes in mouse models [5]. They found that irisin
is released into blood from skeletal muscle after prote-
olysis of the type I membrane protein FNDC5, stimu-
lates uncoupling protein 1 (UCP1) expression, increases
total energy expenditure, and then improves glucose tol-
erance and reduces fasting insulin in animal models [5].
However, there is no evidence available on the pathways
about the relationships among serum irisin, adiposity,
glucose and insulin levels with insulin resistance in
humans, therefore studies are warranted to explore the
potential pathways among them, which may be helpful
in elucidating the mechanisms of insulin resistance.
In the present study based on baseline examination of
the same cohort of 1,115 community-living healthy obese
Chinese adults as our two previous publications [6, 7], we
firstly aimed to examine the independent effect of circulat-
ing irisin levels on insulin resistance. Secondly, different
body composition measurements of adiposity, as well as
their potential interactions with circulating irisin, on insu-
lin resistance will be tested further. Thirdly, we will ex-
plore the possible pathways among circulating irisin,
adiposity, glucose, insulin levels and insulin resistance.
Methods
Study population
The present study was based on the baseline examin-
ation of the same cohort of 1,523 community-living
healthy obese Chinese adults as our two previous publi-
cations [6, 7]. Details on methods of subject sampling,
recruitment and evaluation have been described in these
two publications [6, 7]. Briefly, a total of 1,523 subjects
aged 40 years or older living in the Lianqian community,Xiamen, China with central obesity (waist circumference
greater than 90 cm for men and 80 cm for women) were
recruited. Of them, 1,115 (73.2 %) subjects with the
complete data on the entire examination were left for fur-
ther analysis. The study was approved by the Human Re-
search Ethics Committee of the First Affiliated Hospital of
Xiamen University (Xiamen, China). Written informed
consent was obtained from each participant.
Measurements
Clinical parameters
Anthropometric measurements were obtained using
standard protocols and techniques. After removal of shoes
and heavy clothing, each subject underwent weight, height
and waist circumference measurements, using a calibrated
scale. Body mass index (BMI) was calculated as weight in
kilograms divided by height in squared meters as a meas-
ure of general obesity. Waist circumference was measured
at the midpoint between the inferior costal margin and
the superior border of the iliac crest on the midaxillary
line. Body fat were quantified with the Hologic whole
body DXA systems (Hologic Inc., Bedford, MA). Arterial
blood pressure was measured with a mercury sphygmo-
manometer after sitting for at least 15 min. Blood pressure
measurements were taken according to the Joint National
Committee VII criteria (JNC VII) [15]. Three readings
were taken at 5-min intervals. The mean of the three mea-
surements was recorded.
Biochemical parameters
All blood samples were obtained after 12-h fasting.
Blood and urine samples were refrigerated at −20 °C,
transferred and tested in the central laboratory of the
First Affiliated Hospital, Xiamen University. 75-g oral
glucose tolerance test (OGTT) was conducted for each
subject. Plasma glucose, liver enzyme levels, and serum
lipid profiles, including triglyceride (TG), total choles-
terol (TC), and high-density lipoprotein cholesterol
(HDL-C) were determined on a HITACHI 7450 analyzer
(HITACHI, Tokyo, Japan). Low-density lipoprotein chol-
esterol (LDL-C) was calculated by Friedewald’s formula.
Fasting plasma glucose concentration (FPG) and 2-h
plasma glucose concentration (2-h PG) were measured by
the hexokinase method. Serum fasting insulin concentra-
tion was measured by electrochemiluminiscence immuno-
assay (Roche Elecsys Insulin Test, Roche Diagnostics,
Mannheim, Germany). Serum irisin concentration was
measured using the enzyme-linked immunosorbent assay
(ELISA) kits (Aviscera Biosciences, Santa Clara, CA). The
sensitivity of the assay was 0.2 ng/ml and the linear range
of the standard was 5 to 500 ng/ml. The intra- and inter-
assay variations were both less than 10 %. Homeostasis
model assessment - insulin resistance (HOMA-IR) was cal-
culated using the formula: fasting serum insulin (mU/L)
Table 1 Demographic, lifestyle and clinical characteristics of
subjects by insulin resistance
Insulin Resistance
Variables No Yes P value
Demographics
N (%) 448 (40.1 %) 667 (59.8 %)
Sex 0.765
Female (n, %) 305 (39.8 %) 461 (60.2 %)
Male (n, %) 143 (41.0 %) 206 (59.0 %)
Age (years) 52.8 ± 7.2 53.4 ± 7.2 0.191
Education categories, (n, %) 0.591
Illiteracy 112 (37.1 %) 190 (62.9 %)
Elementary school 138 (41.8 %) 192 (58.2 %)
Middle school 101 (39.5 %) 155 (60.5 %)
High school 58 (40.8 %) 84 (59.2 %)
College or above 39 (45.9 %) 46 (54.1 %)
Life style habits
Ever smoking (n, %) 126 (42.7 %) 169 (57.3 %) 0.334
Ever drinking (n, %) 60 (46.2 %) 70 (53.8 %) 0.194
Regular physical exercise (n, %) 159 (44.0 %) 202 (56.0 %) 0.079
Adiposity measurements
BMI (kg/m2) 26.6 ± 2.4 28.1 ± 3.3 <0.001***
Waist circumference (cm) 91.9 ± 6.0 94.8 ± 7.5 <0.001***
Body fat (%) 33.3 ± 6.1 35.6 ± 7.0 <0.001***
Clinical characteristics
Systolic blood pressure (mmHg) 128.9 ± 16.8 137.4 ± 17.7 <0.001***
Diastolic blood pressure (mmHg) 77.1 ± 10.4 81.7 ± 10.8 <0.001***
Triglyceride (mmol/L) 1.52 ± 0.95 2.11 ± 1.41 <0.001***
Total cholesterol (mmol/L) 5.76 ± 1.00 5.94 ± 1.13 <0.001***
HDL-cholesterol (mmol/L) 1.43 ± 0.29 1.32 ± 0.29 <0.001***
LDL-cholesterol (mmol/L) 3.65 ± 0.93 3.66 ± 1.07 0.878
Fasting glucose (mmol/L) 5.52 ± 0.58 6.59 ± 2.11 <0.001***
2-h PG (OGTT) (mmol/L) 7.40 ± 2.28 10.16 ± 4.64 <0.001***
HbA1c 5.91 ± 0.48 6.40 ± 1.25 <0.001***
Fasting insulin (mU/L) 7.64 ± 1.92 16.15 ± 6.73 <0.001***
HOMA-IR (*10−6mol*U*L−2) 1.87 ± 0.48 4.67 ± 2.44 <0.001***
Irisin-log transformed (ng/ml)a 1.46 ± 2.05 1.19 ± 2.34 0.042*
All percentages are row percentage; except for percentages, all values
are mean ± SD
Abbreviations: BMI body mass index, HDL high-density lipoprotein, HOMA
homeostasis model assessment, IR insulin resistance index, LDL low-density
lipoprotein cholesterol, OGTT oral glucose tolerance test, PG plasma glucose
*p < 0.05, ***p < 0.001
aIrisin was log-transformed to obtain better approximation of
normal distribution
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ance was defined as HOMA-IR ≥ 2.6*10−6mol*U/L2 [16].
Statistical analysis
Data were presented as the mean ± standard deviation
for continuous variables or number and percentage for
categorical variables. Irisin was log-transformed to ob-
tain better approximation of normal distribution. Differ-
ences between subjects were analyzed using one way
ANOVA for continuous variables and chi-square test for
categorical variables.
Multivariable logistic regression was used to calculate
adjusted odds ratio (OR) and 95 % confidence intervals
(CI) of circulating irisin levels and different adiposity
measurements for insulin resistance in different models
with adjustment for potential confounders. In model 1,
age and sex were adjusted for; in model 2, educational
level, smoking and drinking habits and regular physical
exercise plus model 1 were adjusted for; in model 3, sys-
tolic blood pressure and HDL-C plus model 2 were ad-
justed for. Different adiposity measurement, such as
BMI, waist circumference and body fat percentage, were
tested in the multivariable logistic regression models
separately. In each of the multivariable logistic regres-
sion models, interaction effects between serum irisin
and adiposity measurements were tested separately.
Structural equation modeling (SEM) was conducted to
test the relationships among serum irisin, adiposity, glu-
cose and insulin levels with insulin resistance. Standard-
ized path coefficients and the significant direct effects are
presented. In conducting SEM analyses, satisfactory model
fitting was indicated by root mean square error of ap-
proximation (RMSEA) ≤0.10 [17] and by comparative fit
index (CFI) and Tucker-Lewis fit index (TLI) ≥0.90 [18].
Structural equation modeling (SEM) was conducted
using lavaan (0.5–19) package in R3.2.2 [19]; all the
other analyses were performed using Stata14.0 (Stat-
Corp, College Station, TX). All p-values were two-sided
and p-value <0.05 was considered statistically significant.
Results
Of the 1,115 participants, 766 (68.7 %) were female. The
mean age (±SD) of women and men were 53.1 (±7.1)
years and 53.3 (±7.6) years (p = 0.702), respectively [6, 7].
The overall prevalence rate (95 % confidence interval
(CI)) of insulin resistance was 59.8 % (56.9–62.7 %).
Demographic and clinical characteristics stratified by
insulin resistance
Differences in demographics, life style habits, body com-
position measurements and clinical characteristics of
subjects stratified by insulin resistance are presented in
Table 1. Generally, when compared with controls, sub-
jects with insulin resistance had significantly higherlevels of systolic and diastolic blood pressure, triglycer-
ide, total cholesterol, fasting plasma glucose (FPG), 2-h
PG (OGTT), fasting insulin, HbA1c and lower levels of
HDL-C. Subjects with insulin resistance showed
Table 2 Adjusted odds ratios (ORs) with associated 95 %
confidence interval (CI) for insulin resistance
Insulin Resistance
Variables OR 95 % CI P value
Model 1
Serum irisina 0.878 0.776–0.993 0.039*
Adiposity measurements
BMI (kg/m2) 1.212 1.155–1.272 <0.001***
Waist circumference (cm) 1.079 1.056–1.102 <0.001***
Body fat (%) 1.174 1.132–1.217 <0.001***
Interaction effect
Serum irisin* Body fat (%) 0.640
Model 2
Serum irisina 0.875 0.773–0.989 0.034*
Adiposity measurements
BMI (kg/m2) 1.211 1.154–1.271 <0.001***
Waist circumference (cm) 1.079 1.056–1.103 <0.001***
Body fat (%) 1.174 1.131–1.217 <0.001***
Interaction effect
Serum irisin * Body fat (%) 0.624
Model 3
Serum irisina 0.871 0.765–0.991 0.036*
Adiposity measurements
BMI (kg/m2) 1.157 1.101–1.217 <0.001***
Waist circumference (cm) 1.063 1.039–1.086 <0.001***
Body fat (%) 1.132 1.090–1.176 <0.001***
Interaction effect
Serum irisin* Body fat (%) 0.817
Model 1 was adjusted for sex and age
Model 2 was further adjusted for educational level, ever smoking, ever
drinking and regular physical exercise
Model 3 was further adjusted for systolic blood pressure and HDL
* p < 0.05, ***p < 0.001
aOR and 95%CI was expressed as per SD increase of log transformed
serum irisin
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28.7 ± 3.3 v.s. 26.6 ± 2.4 kg/m2; waist: 94.8 ± 7.5 v.s. 91.9 ±
6.0 cm; body fat percentage: 35.6 ± 7.0 % v.s. 33.3 ± 6.1 %; all
p-values < 0.001). Subjects with insulin resistance also
showed significantly decreased serum irisin levels than their
controls (log-transformed irisin levels: 1.19 ± 2.34 v.s. 1.46 ±
2.05 ng/ml, p= 0.042). There was no significant difference of
age, gender, educational level and lifestyle habits between
subjects with and without insulin resistance.
Associations between circulating irisin levels, adiposity
measurements and insulin resistance
Adjusted odds ratios (ORs) with associated 95 % confi-
dence interval (CI) of circulating irisin levels and adiposity
measurements for insulin resistance are shown in Table 2.
In model 1 with adjustment for sex and age, elevated
serum irisin levels were significantly associated with re-
duced risk of insulin resistance, the adjusted OR (95 % CI)
of per standard deviation (SD) increase of serum irisin
was 0.878 (0.776–0.993, p = 0.039). When each of the adi-
posity measurements was added into the model separately,
increasing levels of adiposity, such as BMI, waist circum-
ference and body fat percentage, were all significantly as-
sociated with increased risks of insulin resistance. But
when all the three body composition measures were added
into the model simultaneously, only body fat percentage,
but neither BMI nor waist, was significantly associated
with increased risk of insulin resistance (OR (95 % CI):
1.202 (1.092–1.323), p < 0.001). And there was no signifi-
cant interaction effect between serum irisin and adiposity
measurements on insulin resistance.
In model 2 (additional adjustments for educational level,
smoking and drinking habits and regular physical exercise)
and model 3 (further adjustments for systolic blood pres-
sure and HDL-C), the results were quite similar to those in
model 1. In model 3, the adjusted OR(95 % CI) of per SD
increase of serum irisin for insulin resistance was 0.871
(0.765–0.991, p = 0.039). When all three adiposity measure-
ments were added into the model 3 simultaneously, only
body fat percentage was significantly associated with in-
creased risk of insulin resistance (OR (95 % CI): 1.152
(1.041–1.275), p = 0.006). When serum irisin and body fat
percentage were added into model 3 simultaneously, the ef-
fect of circulating irisin on insulin resistance was attenuated
into marginally significant (OR (95 % CI): 0.879 (0.770–
1.003), p = .055), but the effect of body fat percentage on in-
sulin resistance showed little change. And interaction effect
between serum irisin and adiposity measurement on insulin
resistance was not statistically significant.
Possible pathways for serum irisin leading to insulin
resistance
SEM analysis about the relationships among serum irisin,
adiposity, glucose, insulin and insulin resistance showsthat a one pathway model fits well (χ2 = 44.09, p < 0.001;
CFI–0.994; TLI =0.986; and RMSEA = 0.067) (Fig. 1). The
standardized path coefficients in the path diagrams indi-
cate that serum irisin might lower the risk of insulin re-
sistance indirectly. Increased circulating irisin levels might
lower fasting insulin levels (standardized path coefficient =
−0.046, p= 0.032), which in turn improves insulin resistance.
Adiposity (body fat percentage) is associated with increased
fasting insulin levels and FPG (standardized path coefficient:
0.257 (p < 0.001) and 0.063 (p= 0.032), respectively), which
then increases the risk of insulin resistance. No significant
effect of serum irisin on adiposity or FPG was observed.
Discussion
The present study demonstrated that circulating irisin
levels were significantly decreased in obese Chinese adults
Serum Irisin Adiposity 




-0.064, p=0.032 0.063, p=0.032
Arrows with significant path 
Fig. 1 Structural equation modeling path diagrams for associations among serum irisin, adiposity, plasma glucose, serum insulin and insulin resistance
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vated circulating irisin were independently associated with
reduced risk of insulin resistance. Although obesity has
been conclusively found to be associated with insulin re-
sistance, we found that body fat percentage, but neither
BMI nor waist circumference, was independently associ-
ated with insulin resistance after adjusting for potential
confounders. Our novel finding on possible pathways of
insulin resistance shows that elevated irisin might de-
crease fasting insulin level and then reduce the risk of in-
sulin resistance indirectly, and adiposity might increase
both fasting insulin and FPG levels and therefore induce
insulin resistance.
Myokines secreted by skeletal muscle which has been
considered as the largest endocrine organ have been
suggested to play a key role in glucose and lipid metab-
olism, thus contributing to energy homeostasis and
pathogenesis of insulin resistance related health condi-
tions, such as metabolic syndrome and diabetes [20]. Iri-
sin, a newly identified myokine, was reported to increase
total energy expenditure, improve glucose tolerance and
reduce fasting insulin, drive brown fat-like development
of white fat and then protect diet-induced obesity and
diabetes in mouse models in 2012 [5]. After that, great
interests have been attracted to explore the role of irisin in
humans diseases even therapeutic potentials on obesity
and diabetes [21, 22]. As for the relationship between iri-
sin and insulin resistance in humans, available evidence
has been controversial. Moreno-Navarrete firstly reported
circulating irisin levels were negatively associated withobesity and insulin resistance in men [6]. Negative associ-
ation between circulating irisin levels and HOMA-IR were
also reported by HuW and Huth C et al. [23, 24]. In high-
fat diet induced obese mice, Yang et al. reported that irisin
secretion decreased which contributed to muscle insulin
resistance [25]. Contrastingly, Park et al. found that irisin
was positively associated with fasting glucose and
HOMA-IR in a sample of 151 subjects; and that irisin was
independently associated with HOMA-IR and increased
risk of metabolic syndrome in multiple regression analyses
after adjustment for confounders. They discussed that ei-
ther increased secretion by adipose/muscle tissue and/or a
compensatory increase of irisin to overcome an underlying
irisin resistance in these subjects [9]. Similar findings were
also reported by others [26–28]. Reinehr et al. found that
irisin levels were the highest in obese children with im-
paired glucose tolerance, followed by obese children with
normal glucose tolerance, and were the lowest in normal
weight children. After adjusted for confounders in a mul-
tiple regression analysis, they found that baseline irisin
was significantly associated with HOMA-IR and con-
cluded that irisin concentrations were positively related to
insulin resistance and parameters of metabolic syndrome,
which might be because obese children with features of
metabolic syndrome are in an irisin-resistant state [26]. It
should be noted that the sample sizes of all of the studies
above are quite small. In the present study with a sample
size of 1,115 obese adults, we found that circulating irisin
levels were significantly decreased in those with insulin re-
sistance than those without, and furthermore, elevated
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duced risk of insulin resistance after adjusting for potential
confounders. The controversy about the effect of irisin on
insulin resistance should be tested further, especially by
the designed prospective cohort studies in different
populations.
Bostrom et al. reported that the exercise- and PGC1-α-
induced irisin has been proposed to act as a hormone on
subcutaneous white cells, increasing energy expenditure
in mouse models by means of a program of brown-fat-like
development, which is not yet fully elucidated [5, 29]. Iri-
sin has been suggested to increase total energy expend-
iture, improve glucose tolerance and reduce fasting
insulin, therefore induce improvement of glucose homeo-
stasis, insulin resistance, and obesity-related health condi-
tions [30, 31]. However, no evidence is available on the
possible pathways among serum irisin, adiposity, glucose,
insulin levels and insulin resistance in humans. An novel
finding of the present study on possible pathways for insu-
lin resistance is that elevated circulating irisin levels im-
prove insulin resistance indirectly through decreasing
fasting insulin. We previously reported that fasting insulin
was negatively associated with serum irisin level in a step-
wise multivariable linear regression analysis [6]. The nega-
tive effect of circulating irisin on fasting insulin in obese
adults in the present study was consistent with Bostrom’s
report in mice [5]. But the mechanisms by which irisin de-
creases fasting insulin should be clarified in future. We
did not find any direct effect of serum irisin on either fast-
ing glucose or adiposity, which was also in line with many
previous studies [8, 32].
Obesity has been conclusively found to be associated
with increased risks of insulin resistance, but BMI has
been widely used as the index of obesity in these studies.
Since numerous studies have reported that different mea-
surements of adiposity, such as BMI, waist circumference
and body fat percentage, show different associations with
various health conditions [11–13], therefore effects of dif-
ferent adiposity measurements on insulin resistance
should be explored. The present study found that body fat
percentage, but neither BMI nor waist circumference, was
independently associated with insulin resistance, which
implicated that adiposity per se, rather than body weight
or body shape, is independently associated with increased
risk of insulin resistance. Therefore, decreasing body fat
percentage should be emphasized when dealing with
weight reduction for those obese subjects.
We should be cautious during interpretation of the
present findings due to the following limitations. One
limitation is that HOMA-IR calculated with fasting glu-
cose and fasting insulin levels rather than hyperinsuline-
mic euglycemic clamp, which remains the “gold standard”
for accurately determining insulin resistance, were used in
the present study. The second limitation is that subjectswere not randomly sampled from their living communities
and were all central obese adults, so we cannot extrapolate
our findings to the non-obese adults. The third limitation
is that we are not certain about the temporal sequence be-
tween serum irisin and insulin resistance because of the
cross-sectional study design. Therefore, our results should
be confirmed in the designed prospective cohort studies
or intervention studies in future. Excess adiposity has been
reported to be associated with increased circulating adipo-
kine concentrations, such as leptin, and leptin has been
recently found to down-regulate FNDC5 expression in the
adipose tissue [33, 34]. In the present study, subjects with
insulin resistance showed higher body fat percentage than
their controls, therefore, the inhibitory effect of leptin on
adipose FNDC5 expression may also explain the de-
creased circulating irisin in subjects with insulin resistant.
Therefore, the fourth limitation is that we did not measure
other cytokines, such as leptin, adiponectin, IL-6 and
TNF-α, which may be related to serum irisin level and
may confound the association between irisin and insulin
resistance. We must acknowledge that the detection of
circulating irisin remains largely controversial, since the
commercial antibodies and ELISA assays reveal prominent
cross-reactivity with non-specific proteins in human and
animal sera and ELISA assays have not been widely ac-
cepted as accurate and reproducible [35]. Although the
intra and inter assay variations in the present study were
both less than 10 %, detection of circulating irisin could
be another limitation of the present study. On the other
hand, these limitations do not diminish the value of our
study. Firstly, our study has a relatively large sample size
of obese adults. And we have also adjusted for much more
potential confounders than previous studies. For example,
few previous studies adjusted for physical activity, body
composition measurements, which were important con-
founding factors of serum irisin. Last but not the least, we
are probably the first to report the possible pathways
among circulating irisin, adiposity, glucose, insulin levels
and insulin resistance. By using structural equation mod-
eling, we found that elevated circulating irisin levels im-
prove insulin resistance indirectly through lowering
fasting insulin, which may be helpful to elucidate the
mechanisms of insulin resistance.
Conclusions
In conclusion, based on the baseline examination of the
same cohort of 1,115 community-living healthy obese
Chinese adults as our two previous publications [6, 7], the
present study further demonstrated that circulating irisin
levels were significantly decreased in those with insulin re-
sistance compared to their controls. And elevated circulat-
ing irisin improves insulin resistance indirectly through
lowering fasting insulin, although the underlying mecha-
nisms are not yet fully understood. Furthermore, body fat
Shi et al. BMC Endocrine Disorders  (2016) 16:44 Page 7 of 8percentage, rather than body weight or body shape, is inde-
pendently associated with increased risk of insulin resist-
ance. Therefore, decreasing body fat percentage should be
emphasized for obese subjects to prevent incidence of insu-
lin resistance related health conditions. Future studies
about effects and possible pathways of irisin on insulin re-
sistance with the designed prospective cohort studies and
intervention studies in the general adults are warranted
therefore.
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